Stay updated with breaking news from Fred Saad. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Family doctors use national guidelines to decide whether and when to send their patients for routine cancer screenings — but experts say Canadians' lives are at risk because those guidelines use old data, lack expert advice, and are updated too infrequently.
/PRNewswire/ -- Sumitomo Pharma Canada, Inc., announced today that ORGOVYX® (relugolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, is...
Fred Saad, MD, FRCS, expands on the relationship between PSA responses and survival outcomes in the ARASENS trial, explained the use of 0.2 ng/mL as a standard cut off for undetectable PSA within this exploratory analysis, and discussed how this study elucidates future directions for research with triplet regimens in mHSPC.
Men with metastatic hormone-sensitive prostate cancer treated with Nubeqa, androgen-deprivation therapy and docetaxel had reductions in PSA levels that were associated with improved overall survival and a prolonged time to PSA progression.
Fred Saad, MD, FRCS, discusses prostate-specific antigen (PSA) response and time to PSA progression with the combination of abiraterone acetate and olaparib in patients with metastatic castration-resistant prostate cancer.